Acadia Pharma (ACAD) Halted Ahead of Pivotal Pimavanser Phase III Presentation - InvestingChannel

Acadia Pharma (ACAD) Halted Ahead of Pivotal Pimavanser Phase III Presentation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

Top News Most Read Highlighted

Get Alerts ACAD Hot Sheet

BUY ( Up)

Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) shares are halted Tuesday morning ahead of the company’s conference call and webcast to present the top-line results from its pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis (PDP).

The event will start at 8:00am EST and may be accessed by dialing 866-783-2140 for participants in the U.S. or Canada and 857-350-1599 for international callers (reference passcode 26249437).

After being higher in late trading Monday night, the stock is now flat.

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW